Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluocinolone plus tacrolimus versus fluocinolone plus narrowband UVB for localized morphea
IRCT20091012002581N7Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in morphea comparing Fluocinolone + tacrolimus with Fluocinolone + narrowband UVB (2 arms). Primary endpoints: Waist area, Dyspigmentation and 3 more. Started Apr 2020; status: completed.
02
Drugs
fluocinolonetacrolimus
03
Conditions
morphea
Beyond the preview
Go deeper on IRCT20091012002581N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002581N7.